Cell Biotech achieves European patent for anticancer substance for new drug ‘PP-P8’ for colorectal cancer

Cell Biotech obtained European patent for anticancer substance for new drug ‘PP-P8’ for colorectal cancer. [Photo provided = Cell Biotech]

Microbiome specialized Cell Biotech (CEO Myeong-joon Jeong) announced that they achieved European patent (Registration Number EP3453718) for anticancer substance for new drug ‘PP-P8’ for colorectal cancer.

As achieved European patent followed by Korean patent (Registration Number KR10-1910808) and Japanese patent (Registration Number JP 6586248) they prepared bridgehead of international medicine market advance through global intellectual property securement. It was discovered that the anticancer substance P8 that Cell Biotech found has noticeable curative effect for colorectal cancer. In addition the inhibitory effect for colorectal cancer cell in protein P8 has been proved through experimental rats and primates in the stage of preclinical study and its safety of toxicity and side effect has been confirmed.

Cell Biotech are proceeding with the study for developing colorectal cancer by securing the technology of the patented anticancer substance secreted from Pediococcus Pentosaceus (CBT SL4) which is a lactobacillus kimchi and are waiting for approval of Phase I clinical trials Investigational New Drug (IND) from the Ministry of Food and Drug Safety.

PP-P8 is an oral gene drug based on microbiome using Lactobacillus kimchi inhabited in Korean’s large intestine and it is a First-in-Class new drug for colorectal cancer. As a medication based on safety approved lactobacillus kimchi using gene technique it is expected to help overcome the drawbacks of synthetic chemical compound anticancer drug following side effect due to its higher concentration injection and prolonged use.

Besides the patent of anticancer substance P8 Cell Biotech acquired Korean patent of Lactobacillus Drug Delivery System (DDS) and Gene Expression Cassette their Europe·American·Japanese patents are on track at the same time and enlarge their position in global medicine markets.

Cell Biotech said they are currently proceeding to register their patent in various countries not only in Korea to target global colorectal cancer medicine markets reaching about 12 trillion won annually and they will become a representative company of Korea leading microbiome new medicine development and securement of technological competitiveness by dominating international patents.

Website: : http://www.wip-news.com/news/articleView.html?idxno=6139